Parexel’s Amy McKee, M.D. Named to 2023 PharmaVoice 100
September 20, 2023 08:55 ET
|
Parexel International LLC
DURHAM, N.C., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Parexel Appoints Gwyn Bebb, BM, BCh., Ph.D., to Lead Oncology Clinical Development
September 19, 2023 08:55 ET
|
Parexel International LLC
DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Parexel and Partex Announce Innovative Alliance Leveraging Artificial Intelligence and Big Data to Accelerate Drug Discovery and Development
August 15, 2023 07:00 ET
|
Parexel International LLC
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets ...
Parexel Announces Updates to Board of Directors
June 23, 2023 08:49 ET
|
Parexel International LLC
Goldman Sachs’ Partner, Global co-Head of Private Equity Michael Bruun joins as new Director, succeeding current Goldman Sachs Board member Jo Natauri who is retiring from the firm at the end of the...
Parexel Rated “Top CRO to Work With” in 2023 WCG CenterWatch Global Site Relationship Benchmark Survey for Second Straight Time
May 31, 2023 09:00 ET
|
Parexel International LLC
DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Parexel Appoints Scott Smith, M.D., Ph.D. as New Head of Hematology
April 19, 2023 09:00 ET
|
Parexel International LLC
DURHAM, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Parexel Introduces Expert Series – New Medicines, Novel Insights
February 28, 2023 09:00 ET
|
Parexel International LLC
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...
Parexel Teams with MyEyeDr. to Increase Patient Access and Participation in Ophthalmology Clinical Trials
December 15, 2022 09:00 ET
|
Parexel International LLC
BOSTON and DURHAM, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development...
Parexel Announces Significant Recognition for Diversity and Workplace Culture in Asia/Pacific Region; Reaches Significant Company Milestone in Japan
November 29, 2022 09:00 ET
|
Parexel International LLC
BOSTON and DURHAM, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development...
Parexel Opens Clinical Trial Supplies and Logistics Depot in Suzhou, China
September 27, 2022 16:30 ET
|
Parexel International LLC
New depot offers local and international biopharmaceutical customers timely access to supplies and medications for clinical trial sites and patientsto accelerate clinical trials in the region BOSTON...